MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze TEVA →
    • FindStock Picks / Stock Screener
    • Value · TEVAIntrinsic Value Calculator
    • Invest · TEVAInvestment Case
    • Hold · TEVA5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
TEVA stock logo

TEVA

Teva Pharmaceutical Industries Limited

$44.5
0.85
 (1.95%)
Exchange:  NYSE
Market Cap:  51.924B
Shares Outstanding:  1.149B
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Drug Manufacturers – Specialty & GenericView industry performance
   
CEO:  Richard D. Francis
Full Time Employees:  32008
Address: 
124 Dvora Hanevi’a Street
Tel Aviv
TA
6.944M
IL
Website:  https://www.tevapharm.com
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company’s diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington’s disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.

Click to read more…

Revenue Segmentation

Revenue by type

Revenue by region

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Log in — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
TETEVA logoTEVATeva Pharmaceutical Industries Limited51.9B98.921.66.3%
HLHLN logoHLNHaleon plc40.2B19.016.56.5%
TATAK logoTAKTakeda Pharmaceutical Company Limited68.1B28.347.74.6%
ZTZTS logoZTSZoetis Inc.34.1B14.213.320.9%
VTVTRS logoVTRSViatris Inc.23.9B—8.1-0.3%
ELELAN logoELANElanco Animal Health Incorporated13.4B—22.94.4%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/04/29 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue15,845,00016,544,00017,257,000
Gross Profit7,645,0008,063,0008,938,000
EBITDA1,558,0004,431,0003,141,000
Operating Income433,000-303,0002,157,000
Net Income-559,000-1,639,0001,410,000

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets43,479,00039,326,00040,747,368
Total Liabilities35,353,00033,606,00032,833,491
Total Stockholders Equity7,506,0005,380,0007,909,877
Total Debt20,153,00018,079,00017,381,731
Cash and Cash Equivalents3,226,0003,300,0003,555,945

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow1,368,0001,247,0001,649,000
Capital Expenditure-526,000-498,000-501,000
Free Cash Flow842,000749,0001,148,000
Net Income-615,000-1,959,0001,410,000
Net Change in Cash393,00073,000256,000

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)19,172,764.921Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)19,829,630.737Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)19,569,916.100Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)7,175,965.609Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)7,421,477.386Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)7,324,404.129Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)4,713,665.314Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)4,924,922.614Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)4,841,393.284Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)4,324,497.614Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)4,472,656.456Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)4,414,076.729Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)4.130Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)4.200Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)4.020Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)5Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)2Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
16.51B  ?P/S
 (TTM)
: 
3.01
?Net Income
 (TTM)
: 
-1.639B  ?P/E
 (TTM)
: 
98.89
?Enterprise Value
 (TTM)
: 
64.823B  ?EV/FCF
 (TTM)
: 
52.45
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
6.35%  ?ROIC
 (TTM)
: 
6.33%
?Net Debt
 (TTM)
: 
14.866B  ?Debt/Equity
 (TTM)
: 
2.13
?P/B
 (TTM)
: 
6.5  ?Current Ratio
 (TTM)
: 
0.95

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
21.60Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates TEVA intrinsic value between $42.67 – $55.19 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate TEVA Intrinsic Value

Common questions about TEVA valuation

Is Teva Pharmaceutical Industries Limited (TEVA) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Teva Pharmaceutical Industries Limited (TEVA) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is TEVA a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether TEVA trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is TEVA’s P/E ratio?

You can see TEVA’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for TEVA?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is TEVA a good long-term investment?

Whether TEVA fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Teva Pharmaceutical Industries Limited

  • Teva Pharmaceutical Industries Limited intrinsic value calculatorEstimate what the business is worth
  • Teva Pharmaceutical Industries Limited 5-year outlookWhat has to go right, and what could go wrong
TEVA

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

1.95
MarketSnap

Trading Metrics:

Open: 43.91   Previous Close: 43.65
Day Low: 43.44   Day High: 44.57
Year Low: 24.01   Year High: 44.57
Price Avg 50: 40.03   Price Avg 200: 35.05
Volume: 7.467M   Average Volume: 5.918M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

What Teva Pharmaceutical Industries (TEVA) Said on Its Q3 Earnings Call
04-11-2026 05:16
What Teva Pharmaceutical Industries (TEVA) Said on Its Q3 Earnings Call
Teva Pharm to grow more in 2027 despite US' IRA impact on Austedo
03-11-2026 10:11
Teva Pharm to grow more in 2027 despite US' IRA impact on Austedo
Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.
03-11-2026 05:00
Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.
Why Is Teva Stock Trading Lower on Monday?
02-11-2026 10:01
Why Is Teva Stock Trading Lower on Monday?
What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q3 Earnings
29-10-2026 10:16
What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q3 Earnings
TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia
12-10-2026 13:10
TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze TEVA →
    • FindStock Picks / Stock Screener
    • Value · TEVAIntrinsic Value Calculator
    • Invest · TEVAInvestment Case
    • Hold · TEVA5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Settings
    • Public profile ↗
  • Log in

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.